Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Abstract

Objective:

Leucyl-tRNA synthetase (LRS) is an aminoacyl-tRNA synthetase catalyzing ligation of leucine to its cognate tRNA and is involved in the activation of mTORC1 by sensing cytoplasmic leucine. In this study, the usefulness of LRS as a therapeutic target of non-small cell lung cancer (NSCLC) and the anticancer effect of the LRS inhibitor, BC-LI-0186, was evaluated.

Methods:

LRS expression and the antitumor effect of BC-LI-0186 were evaluated by immunohistochemical staining, immunoblotting, and live cell imaging. The in vivo antitumor effect of BC-LI-0186 was evaluated using Lox-Stop-Lox (LSL) K-ras G12D mice.

Results:

LRS was frequently overexpressed in NSCLC tissues, and its expression was positively correlated with mTORC1 activity. The guanosine-5’-triphosphate (GTP) binding status of RagB was related to the expression of LRS and the S6K phosphorylation. siRNA against LRS inhibited leucine-mediated mTORC1 activation and cell growth. BC-LI-0186 selectively inhibited phosphorylation of S6K without affecting phosphorylation of AKT and leucine-mediated co-localization of Raptor and LAMP2 in the lysosome. BC-LI-0186 induced cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3 and increase of p62 expression, showing that it has the autophagy-inducing property. BC-LI-0186 has the cytotoxic effect at nanomolar concentration and its GI₅₀ value was negatively correlated with the degree of LRS expression. BC-LI-0186 showed the antitumor effect, which was comparable with that of cisplatin, and mTORC1 inhibitory effect in a lung cancer model.

Conclusions:

BC-LI-0186 inhibits the noncanonical mTORC1-activating function of LRS. These results provide a new therapeutic strategy for NSCLC and warrant future clinical development by targeting LRS.

Keywords

aminoacyl-tRNA synthetase (ARS)BC-LI-0186 leucyl-tRNA synthetase (LRS)mTORC1 non-small cell lung cancer (NSCLC)

Introduction

Lung cancer is the third most common malignancy and still the leading cause of cancer death in the world. In the United States, it is projected that there may be approximately 222,500 new cases and 155,870 deaths from lung cancer in 2017.¹ The development of target agents and immunotherapy has improved treatment outcomes, but ultimate resistance to these therapies requires new approaches to combat carcinogenesis and resistance to current therapies.²

Aminoacyl-tRNA synthetases (ARSs) are housekeeping enzymes that contribute to protein synthesis by catalyzing the ligation of specific amino acids to their corresponding tRNAs.^3,4 ARSs bind ATP and an amino acid to form an aminoacyl adenylate and deliver the activated amino acid to the 3’-end of a tRNA.⁵ ARSs are divided into two classes: Class I synthetases have a nucleotide-binding Rossmann fold,⁶ whereas class II synthetases share a different catalytic domain.⁷ In addition to their role in protein synthesis, mammalian ARSs have other domains that enable them to perform noncanonical functions. For example, tryptophanyl- and tyrosyl-tRNA synthetases control angiogenesis and immune responses in the tumor microenvironment.^8–10 Other ARSs play noncanonical roles by forming complexes with ARS-interacting multifunctional proteins.⁵ For example, lysyl-tRNA synthetase is involved in the development of melanoma through binding to the microphthalmia-associated transcription factor, and glutamyl-prolyl-tRNA synthetase is a translational silencer that suppresses vascular endothelial growth factor A.^11,12

Leucyl-tRNA synthetase (LRS), which catalyzes ligation of _L-Leu to its cognate tRNA, is a class I ARS with a large insertion connective peptide 1 (CP1) domain, a tRNA anticodon-binding domain, and a C-terminal extension domain.¹³ Recent studies have shown that LRS possesses another important noncanonical function: it is required for leucine-mediated mTORC1 activation. LRS binds and activates Rag GTPase in an amino-acid-dependent manner; Rag GTPase then activates mTORC1.^14–17 These findings suggest that LRS overexpression can impact cancer progression and that LRS inhibitors are thus potential anticancer therapeutics. The compound BC-LI-0186 specifically inhibits the GTPase activating the function of LRS through binding to the RagD interacting site of LRS and inhibits lysosomal localization of LRS and mTORC1 activity. Furthermore, BC-LI-0186 showed the growth inhibiting activity in the cancer cells that express drug-resistant mTOR mutations.¹⁸

Missense mutations of KRAS, which introduce an amino acid substitution at position 12 or 13, results in constitutive activation of KRAS signaling and is one of the most common driver mutations in lung adenocarcinoma.^19,20 However, appropriate therapeutic modality has not yet been developed for these subtypes of lung cancer in the metastatic setting and it is still one of the representative area of unmet need in the medical area. Activating mutation of KRAS induces cellular proliferation through constitutive activation of RAS → RAF → MEK → ERK signaling and activated ERK activates mTORC1 through inhibition of TSC. Meanwhile, activated KRAS can also induce mTORC1 activation through activation of the PI3K–AKT pathway.²¹ Therefore, the mTORC1 signaling pathway is one of the key targets in lung adenocarcinoma with KRAS activation mutation, although conventional rapalogs targeting FKBP-12 have limited effect as a single therapeutic agent. Therefore, we investigated the effect of novel mTORC1 inhibitor, BC-LI-0186, on the K-ras mouse lung cancer model.

In this study, we measured the expression of LRS and pS6, a marker of mTORC1 signaling, in non-small cell lung cancer (NSCLC) tissues. Using NSCLC cells, we assessed the effects of BC-LI-0186 on LRS and mTORC1 activity and confirmed its cytotoxic activity. The potential utility of BC-LI-0186 as a lung cancer therapeutic was tested using a K-ras mouse lung cancer model. This study provides evidence that BC-LI-0186 inhibits the noncanonical, mTORC1-activating function of LRS and could be useful as a therapeutic for NSCLC. Additional studies are needed to identify noncanonical functions of ARSs and to assess their potential as targets for cancer therapeutics.

Materials and methods

Study materials

Anti-actin (I-19) and anti-β-tubulin were purchased Santa Cruz Biotechnology (Dallas, TX, USA), rabbit polyclonal anti-RRAGD from Bethyl Laboratories (Montgomery, TX, USA), anti-Leucyl-tRNA synthetase (LRS) from Neomics (Suwon, Korea). Unless otherwise noted, antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Guanosine-5’-triphosphate (GTP) mutant of RagB (Flag pLJM1 RagB Q99L, Plasmid #19315) and GDP mutant of RagD (Flag pLJM1 RagD S77L Plasmid #19317) were obtained from addgene.²² The leucine free (Cat #ML011-96) and amino acid (Cat #ML011-82) free cell culture media were purchased from Welgene (Gyeongsan-si, Korea). The 11 NSCLC cells used in this study were H1703, H1299, H2009, H460, A549, H1650, H596, HCC2228, SNU1330, H2279, and H358 obtained from ATCC (https://www.atcc.org/). A set of 117 NSCLC tissues from patients who underwent pulmonary resection between 2000 and 2008 and had submitted written consent providing the residual samples were randomly selected from the institutional tissue archive. To evaluate LRS expression, a formalin-fixed paraffin-embedded lung cancer tissue slide from each patient was analyzed by immunohistochemistry (IHC). The relationship between the expression of pS6 and LRS was evaluated using the serial section slides from the same formalin-fixed paraffin-embedded tissue block. This study was approved by the Institutional Review Board (IRB) of Gangnam Severance Hospital (IRB #3-2014-0299) and was carried out in compliance with the Declaration of Helsinki and Korean Good Clinical Practice guidelines. Lox-Stop-Lox (LSL) K-ras G12D mice were obtained from the NCI Mouse Repository, bred, and genotyped according to the supplier’s guidelines (https://ncifrederick.cancer.gov/Lasp/MouseRepository/Default.aspx). A total of 26 K-ras G12D mice, including five vehicles, eight cisplatin, seven BC-LI-0186, and six combination treatment mice were used for the experiment. This animal study was approved by our Institutional Animal Care and Use Committee (#2013-0278-1), following guidelines from the American Association for the Assessment and Accreditation of Laboratory Animal Care. AdCre virus was obtained from the Gene Transfer Vector Core of the University of Iowa (Iowa City, IA, USA).

Immunoblotting

Cells were harvested using 2×LSB lysis buffer containing protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA) on ice. After sonication, 30 mg of lysate was separated by gel electrophoresis on a 7.5–12% polyacrylamide gel and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories Inc., Richmond, CA, USA). The expression level of each protein was measured using ImageJ (http://rsbweb.nih.gov/ij/) and quantified relative to β-actin.

RagB, RagD GTP-agarose bead pull-down assay

Tissue lysates were incubated with 100 µl GTP-agarose beads (Sigma-Aldrich, cat no. G9768) in 0.5 ml of GTP-binding buffer for 30 min at 4°C. The beads were washed with GTP-binding buffer, and the supernatant was retained. Then retained supernatant was incubated with beads for another 30 min. The beads were washed again, then incubated with the retained supernatant overnight at 4°C. After washing five times with GTP-binding buffer, GTP-bound protein extracts were eluted with 2× sample buffer and GTP-bound protein was visualized by immunoblotting.

Cell growth, viability assays, and flow cytometer

NSCLC cells were plated in 96-well plates, incubated for 24 h, and then treated with the indicated dose of BC-LI-0186 diluted in the media containing CellTox Green Dye (Promega, G8731). The cell growth and death were measured by photographing the confluency and green fluorescence of the well every 2 h from drug treatment for 24 h using the incuCyte Zoom System (Essen Bioscience). Briefly, cell growth was estimated from the cell confluency of each well. Values denoting cell growth in each reagent-treated well was the relative cell confluency to those obtained from the vehicle-treated wells. For the measurement of cell death, the green fluorescence spot was measured after adding CellTox green (promega, G8731, protocol attached) onto the media, and the values obtained from each treated well were normalized from those from the vehicle-treated wells. The growth and inhibition curves, half maximal inhibitory concentration (IC₅₀), and half maximal effective concentration (EC₅₀) were calculated using Graph Pad Prism (Version 5.01). To measure apoptotic cell death, cells were treated with the indicated dose of BC-LI-0186 or rapamycin for 48 h, stained with annexin V and propidium iodide (PI), and analyzed using a FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).

Immunocytochemistry and IHC

Cells were plated on the cover glasses in a 24-well plate and, at 50% confluency, cells were incubated in leucine-free RPMI media and treated with 10 μM of 0186 for 16 h. The next day, cells were stimulated with 0.8 mM of leucine for 10 min, fixed and permeabilized with cold methanol. After incubation in the primary antibody mixture in 1% bovine serum albumin (BSA) in PBS-T (10× concentrated phosphate buffered saline [PBS] supplemented with Tween 20) for 1 h, cells were visualized with the mixture of secondary antibodies and incubated in 4’,6-diamidino-2-phenylindole (DAPI) in PBS. Cell imaging was performed with a confocal laser-scanning microscope (Zeiss, LSM780) and images were captured with the ZEN2012 software (Zeiss) and stored as CZI image format. IHC staining was performed according to the manufacturer’s protocol using the LABS2 system (Dako, Carpentaria, CA, USA). Briefly, sections were deparaffinized, rehydrated, immersed in H₂O₂–methanol solution, and incubated overnight with primary antibodies against activated caspase-3, pS6, pAKT, pGSK-3β, or LRS at 1:100 dilution in antibody diluent (Dako). Sections were incubated for 10 min with a biotinylated linker and processed using avidin/biotin IHC techniques. The chromogen 3,3’-diaminobenzidine (DAB) was used in conjunction with a Liquid DAB Substrate Kit (Novacastra Laboratories Ltd., Newcastle, UK). LRS expression was scored as the product of staining intensity and percentage of positive tumor cells. Staining intensity was classified as 0, 1, 2, or 3 and frequency as 0 (<10%), 1 (10–50%), 2 (51–80%), or 3 (>80%). Expression was scored as the product of intensity and frequency, and overexpression was defined as expression ⩾6. The scoring system used for pS6 was adapted from Shin et al.²³ Briefly, staining intensity was classified as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong), and frequency was classified as 0 (negative), 1 (1–25%), 2 (26–50%), 3 (51–75%), or 4 (>75%). Expression of pS6 was scored as the sum of staining intensity and frequency. The staining and quantification of p-AKT Ser473 was adapted from Kim et al.¹⁹ Staining intensity was classified as 0, 1, 2, and 3 where intensity two means equal as that of positive control, breast ductal cancer tissue. Frequency was classified as 0, 1 (trace <5%), 1 (–10%), 2 (−30%), and 3 (>30%). The score was obtained by the product of intensity and frequency.

RT-PCR analysis

A549 or H460 cells were treated with DMSO or inhibitor for 6 h or 12 h. For LRS knockdown experiment, Cells were transfected with control siRNA or LRS-targeting siRNA for 48hr. Total RNA was isolated from cells using MiniBEST Universal RNA Extraction Kit (TAKARA). Each RNA (1ug) was reverse-transcribed into cDNA using PrimeScript™ 1st strand cDNA Synthesis Kit (TAKARA). Reverse transcription polymerase chain reaction (RT-PCR) was performed using EmeraldAmp® GT PCR Master Mix (TAKARA), then PCR products were analyzed by 1% agarose gel electrophoresis. Gene expression levels were determined using ImageJ and normalized to the housekeeping gene, GAPDH. All RT-PCR data were analyzed by using Student’s t-test, and error bars in figures represent the standard deviation (SD) of three biological experiments. Primer sequences are as follows: human LRS forward, TAAATTTGGGAAGCGGTATAC; human LRS reverse, GCATTGGGAGAACATAGATCACC; human SREBP-2 forward, CTTTCAAGTCCTTCAGCCT; human SREBP-2 reverse, CAGGCATTGTGGTCAGAAT; human HMGCR forward, ATATTGCTCGTGGAATGGC; human HMGCR reverse, GAGAAGGATCAGCTATCCA.

Mouse imaging and CT image analysis

LSL K-ras G12D mice inhaled 5 × 10⁷ plaque-forming units (PFU) of AdCre virus at 8 weeks after birth.²⁴ At 24 ± 2 weeks after AdCre particle inhalation, with mice under isoflurane anesthesia, a microcomputed tomography (µCT) scan was taken using an eXplore Locus Micro CT Scanner (GE Healthcare, Little Chalfont, UK; 45 μm resolution, 80 kV, 450 μA). Mice were randomized according to tumor burden and received either vehicle (10% dimethylacetamide and 10% Tween 80 in phosphate-buffered saline), BC-LI-0186 (20 mg/kg bid, 5 days per week, i.p.), cisplatin (5 mg/kg, weekly, i.p.), or a combination of both drugs for 2 weeks. Mice were sacrificed after the second µCT scan, and expression of activated caspase-3 and other proteins was analyzed by IHC. Treatment response was evaluated by CT image analysis. To measure the area of a tumor, at least three representative axial CT images were selected from the upper, middle, and lower levels of the lung. Briefly, at least three axial images were selected after reviewing entire scanned images using following criteria: (1) the tumor was precisely separated from the surrounding normal structures; (2) it had a measurable form; (3) the section containing the longest diameter of the mass. To select axial images of same lesion of one tumor before and after treatment, we referred to the bronchial and pulmonary vascular structures. The pixel of tumor area was quantified using Adobe Photoshop (Adobe Systems, San Jose, CA) and Paint.Net (dotPDN LLC., Kirkland, WA, USA) and the change of the tumor area (%) before and after treatment was estimated by the equation (Pixel_before – Pixel_after)/Pixel_before × 100 and averaged over the three images.²⁵

Statistical analysis

The paired t-test was used to compare protein expression in paired samples between tumor and normal-appearing tissue lysates. For the comparison of continuous variables of independent groups, independent sample t-tests were used. Differences in the change in tumor area between groups were analyzed using the Mann–Whitney U test. SPSS software (v23; SPSS, Chicago, IL, USA) was used for statistical analysis. All statistical analyses were two-tailed, and a p-value < 0.05 was interpreted to indicate statistical significance.

Results

LRS expression in NSCLC is related to mTORC1 activity

Because LRS plays a major role in activating the mTORC1 pathway by sensing leucine in the cytoplasmic nutrients,¹⁶ we first questioned whether there is a relationship between the level of LRS expression and the activity of mTORC1. To confirm this, immunoblotting was performed on the LRS and the component of mTOR signaling using 12 lung origin cell lines. The expression level of LRS, detected in the majority of lung cancer cells, was not correlated with the phosphorylation of ERK and showed inverse correlation with phosphorylation of AKT. However, it was clearly positively correlated with phosphorylation of S6K and S6, which represent mTORC1 activity (Figure 1a–e).

In order to further confirm the relationship between the expression level of LRS and the activity of mTORC1, IHC staining was performed using serial tissues sections from 117 NSCLC cases (Figure 1f–i). The demographic characteristics of the study cases are noted in Table 1. There was significant positive correlation between cytoplasmic expression of LRS and that of pS6 in these study sets (Pearson’s r = 0.3246, p-value < 0.001; Figure 1h). To identify the relationship between the expression of LRS in NSCLC tissues and clinical and pathologic parameters, overexpression was set as a staining score 6 or more, and then analyzed. LRS was overexpressed in the cytoplasm of NSCLC cells in 52 (44.5%) out of 117 cases. The cases with cytoplasmic LRS overexpression were older than those without overexpression (58.46 ± 10.58 versus 62.79 ± 9.46 years, t-test p = 0.023); other clinical and pathological parameters including clinical outcome were not associated with LRS overexpression (Table 1 and Supplemental Data 1). The effect of LRS expression on clinical outcome of NSCLC was further evaluated using a publicly available dataset from The Cancer Genome Atlas. Of 520 cases of lung adenocarcinoma, 32 (6%) showed a high LRS mRNA level (Z score ⩾2). However, there was no significant difference in disease-free survival (DFS) or overall survival (OS) in these cases versus cases with a normal LRS mRNA level (Z score <2) (Supplemental Data 2).

Table 1.

Clinical characteristics of the patients according to leucyl-tRNA synthetase (LRS) expression.

		LRS expression		p-value
		Low (0–5)	High (6–9)
		n = 65	n = 52
Age		58.46 ± 10.58	62.79 ± 9.46	0.023^*
Gender	Male	51	35	0.208^**
	Female	14	17
Smoking history†	Never	14	15	0.107
	Former	23	8
	Current	22	24
Pack-year (years)		26.98 ± 21.35	27.59 ± 23.13	0.890^*
Maximal tumor diameter		3.92±1.71	4.47±2.39	0.155^**
Pathology
	Adenocarcinoma	32	26	0.523
	Squamous cell carcinoma	33	25
	Other	0	1
pStage	I	21	17	0.999
	II	15	12
	III	28	22
	IV	1	1

Independent sample t-test.

χ²-test.

†

Smoking history of nine cases is missing.

The relationship between LRS expression and mTORC1 activity was additionally evaluated using paired lung cancer and adjacent normal-appearing lung tissue lysates by immunoblotting and GTP-agarose pull-down assay (Figure 1j–l). Of 15 paired of cases, 12 (80%) showed increased LRS expression in tumor tissue lysate than normal-appearing lung tissue lysates. Similarly, phosphorylation of S6K was higher in 8 (53.3%) cases of tumor tissue lysates when compared with matched normal-appearing lung tissue lysates and showed that there is a clear positive relationship between S6K phosphorylation and LRS expression. Because RagB/RagD heterodimer has higher affinity for LRS than RagA/RagD heterodimer and heterodimer of RagB-GTP/RagD-GDP activates mTORC1, GTP-agarose pull-down assays performed using these paired tissue lysates.^16,22 The GTP-agarose pull-down of RagB was significantly increased in the tumor tissues lysates whereas that of RagD was decreased when compared with the normal-appearing adjacent tissues lysates, suggesting that the GTP-bound status of RagB/RagD is significantly related to the expression of LRS and mTORC1 activity. In summary, LRS is frequently overexpressed in NSCLC tissues, and its expression correlated with mTORC1 activity.

LRS plays an important role in leucine-mediated mTORC1 activation and cell growth

To confirm whether LRS mediates the activation of mTORC1 by leucine and participates in cell growth, siRNA against LRS was transfected to the NSCLC cells expressing high level of LRS. In the cells transfected with control siRNA, leucine induced phosphorylation of S6K, but phosphorylation of S6K by leucine was not observed in the cell line transfected with siRNA against LRS (Figure 2a). In addition, when cell growth was observed for 48 h after LRS silencing using live cell imaging system, significant inhibition of cell growth was observed in the cells transfected with siRNA against LRS comparing those transfected with control siRNA (Figure 2b). SREBP-2 and HMGCR, which are part of the cholesterol biosynthetic gene, are well-known downstream target genes for mTORC1.²⁶ To demonstrate that LRS is involved in the activity of mTORC1, mRNA expression of SREBP-2 and MHGCR was evaluated after LRS knockdown. Indeed, silencing of LRS induced the suppression of mRNA expression of SREBP-2 and MHGCR. (Figure 2c and d). To confirm the interaction between LRS and RagB / RagD in cell growth and proliferation, A549 and H460 cells were co-transfected with GTP mutant of RagB (Q99L) and GDP mutant of RagD (S77L) in the presence of LRS siRNA and were observed using live cell imaging system. In 48 h, inhibition of cell growth by siRNA against LRS was significantly restored by co-transfection of RagB^GTP/ RagD^GDP, indicating that overexpression of active RagB/D could overcome inhibition of cell growth by LRS knockdown (Figure 2e). To observe the underlying mechanism of cell growth inhibition by LRS knockdown, hydroxychloroquine, an autophagy inhibitor, was treated in LRS knockdown cells and cell growth was monitored. Hydrox-ychloroquine inhibited cell growth in the control cells whereas it did not inhibit cell growth in LRS silenced cells, suggesting that suppression of LRS inhibit cell growth through induction of autophagy (Figure 2f). Taken together, LRS plays an important role in the leucine-mediated mTORC1 activation and could be an important therapeutic target in NSCLC.

BC-LI-0186 inhibits the leucine-sensing function of LRS in mTORC1 signaling

BC-LI-0186 binds to the RagD-interacting site of LRS and further specifically inhibits the GTPase activating protein (GAP) activity of LRS.¹⁸ To confirm that BC-LI-0186 is an LRS inhibitor, we first tested its effect on mTOR signaling in NSCLC cells (Figure 3a and b). Treatment of cells with BC-LI-0186 inhibited phosphorylation of S6K in a dose- and time-dependent manner. In the dose-dependent experiments, that harvested cells 15 min after treatment, inhibition of phosphorylation of S6K was observed from 0.2 μM, but the effect on phosphorylation of AKT (S473) was not observed. Treatment of BC-LI-0186 induced cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3 and an increase of p62 from 6 h, suggesting that it has the property of inducing the activity of autophagy, which is a common characteristic of the mTORC1 inhibitor. Decrease of p-AKT was prominent at longer exposure to the BC-LI-0186 and these time points correspond to the emergence of cleaved PARP and activated caspase-3, suggesting that decrease of p-AKT related to the early cell death. For the clarification of mTORC1 inhibitory effect of BC-LI-0186, its effect on the SREBP-2 and MHGCR mRNA expression was compared in the cells treated with rapamycin and INK128, mTORC1 and mTORC1/2 inhibitor respectively. In the BC-LI-0186 treated cells, suppression of SREBP-2 and MHGCR mRNA expression was comparable with the rapamycin and INK128 (Figure 3c and d).

When stimulated by nutrients and Rags, mTORC1 translocates to the lysosome and is activated by GTP-bound Rheb on the surface of the lysosome.²⁷ To further evaluate the effect of BC-LI-0186 on mTORC1, we measured its effect on leucine-induced colocalization of Raptor, a component of mTORC1, and LAMP2, a lysosomal marker (Figure 3e). In untreated cells, leucine stimulation induced colocalization of Raptor and LAMP2, while colocalization was not observed in BC-LI-0186 pretreated cells. To test whether BC-LI-0186 inhibits mTORC1 signaling by repressing the leucine-sensing function of LRS, the effects of amino acids and leucine on mTOR signaling were evaluated in cells pretreated with BC-LI-0186. The addition of amino acids increased phosphorylation of S6K and S6 in untreated cells, while pretreatment with BC-LI-0186 inhibited phosphorylation of S6K and S6 (Figure 3f). There were subtle differences in the phosphorylation of AKT by nutrient supplementation and drug treatment between A549 and H460 cells, which may attribute to the different activating mutations between A549 and H460 cells. A549 cells have functional mutations in the KRAS and LKB genes whereas H460 cells have not only in the KRAS and LKB gene but also activating mutations in the PI3K (p.E545K) gene.^28,29 Leucine supplementation increased phosphorylation of S6K and S6 specifically, and BC-LI-0186 pretreatment suppressed this leucine-mediated S6K and S6 phosphorylation (Figure 3g). Taken together, these results show that BC-LI-0186 inhibits mTORC1 activity through repression of LRS-mediated leucine sensing.

BC-LI-0186 has the cytotoxic effect at nanomolar concentration in NSCLC cells

To confirm that BC-LI-0186 could be developed as a therapeutic agent for lung cancer, the cytotoxicity and growth inhibitory effect were evaluated on several NSCLC cells. NSCLC cells were treated different dose of BC-LI-0186 and cell growth and death were monitored every 2 h by counting the cell confluency and green fluorescence under live cell imaging system, respectively (Figure 4a–f). The BC-LI-0186 IC₅₀ and EC₅₀ were 98 ± 0.89 nM and 183 ± 1.83 nM in A549 cells and 206 ± 0.78 nM and 534 ± 2.91 nM in H460 cells. The same experiment was carried out for the other nine NSCLC cells, and the IC₅₀ and EC₅₀ were shown in Table 2. There was a significant negative correlation between the degree of LRS expression shown in the Figure 1 and the GI₅₀ value of BC-LI-0186 in the NSCLC cell lines (Figure 4g). Rapamycin, a prototypic drug of Rapalog such as temsirolimus, everolimus, and ridaforolimus, inhibits mTORC1 by binding to FK-binding protein 12 (FKBP-12). Because both Rapalog and BC-LI-0186 inhibit mTORC1 activity but target at different sites of signaling pathway, we compared the difference in the growth inhibitory effect and cell death between the two drugs. For this, several NSCLC cell lines were treated with 10 μM of BC-LI-0186 or rapamycin for 48 h, and apoptotic cell death was measured by flow cytometry using annexin V-PI staining (Supplemental Data 3). The representative data obtained from H460 cells by treating indicated dose of BC-LI-0186 for 48 h are shown in the Figure 4h. These findings suggested that BC-LI-0186 has highly effective cytotoxic effect comparing rapamycin in some cells and the cytotoxic effect of BC-LI-0186 did not correspond with that of rapamycin. Neither BC-LI-0186 nor rapamycin had a significant effect on cell cycle progression at the concentration used, and there was no difference in cell cycle progression between drug-sensitive and drug-resistant cell lines (data not shown).

Table 2.

IC₅₀ and EC₅₀ of BC-LI-0186 in non-small cell lung cancer (NSCLC) cells.

Lung cancer cells	IC₅₀ (nM)	EC₅₀ (nM)
H2228	55 ± 1.27 nM	146 ± 2.01 nM
H1703	78 ± 3.18 nM	158 ± 3.19 nM
SNU1330	83 ± 0.31 nM	188 ± 2.07 nM
H1650	86 ± 1.01 nM	106 ± 0.88 nM
A549	98 ± 2.13 nM	183 ± 1.12 nM
H2009	102 ± 1.05 nM	215 ± 0.89 nM
H358	109 ± 2.38 nM	329 ± 0.67 nM
H2279	128 ± 1.99 nM	289 ± 0.73 nM
H460	206 ± 0.78 nM	534 ± 2.91 nM
H596	206 ± 0.89 nM	534 ± 3.19 nM
H1299	1850 ± 0.19 nM	2345 ± 1.91 nM

Anticancer effect of BC-LI-0186 in the K-ras mouse lung cancer model

We then assessed whether BC-LI-0186 could be applied to the treatment of lung cancer using an LSL K-ras G12D lung cancer animal model. Tumor size was measured using µCT and the tumor size changes before and after treatment was compared among the groups treated with vehicle, cisplatin, BC-LI-0186, or a combination of BC-LI-0186 and cisplatin (Figure 5a). BC-LI-0186 was administered at 50 mg/kg bid (i.p.) for 5 days per week for 2 weeks. Treatment with BC-LI-0186, cisplatin, and a combination of both drugs significantly reduced tumor size compared with treatment with vehicle, and the antitumor effects of BC-LI-0186 and cisplatin were comparable (Figure 5b and c). To further evaluate the antitumor effect of BC-LI-0186, mice lungs were harvested after treatment, and hematoxylin and eosin (H&E) and IHC staining for activated caspase-3 was performed. The number of activated caspase-3-positive cells was significantly higher in the BC-LI-0186-treated group than in the vehicle or cisplatin-treated groups (Figure 5d and e). To confirm the effect of BC-LI-0186 on mTORC1 and mTORC2 signaling in vivo, IHC staining was performed for p-S6 and p-AKT, markers for mTORC1 and mTORC2 activity, respectively. Treatment with BC-LI-0186 reduced p-S6 and p-AKT level, whereas cisplatin alone has minimal effect on both p-S6 and p-AKT expression (Figure 5f and i). To assess how well the mice tolerated the treatment, change in body weight during the treatment period was compared among treatment groups. The BC-LI-0186-treated group showed a slight (not statistically significant) increase in body weight during the treatment period, whereas the combination-treatment group showed a slight decrease (Figure 5j). Taken together, these results indicate that treatment with BC-LI-0186 showed a significant antitumor effect in the K-ras mouse lung cancer model, comparable to treatment with cisplatin but with specific inhibition of mTORC1 and not mTORC2.

Discussion

The findings of this study provide further evidence that LRS is involved in mTORC1 activation, and that an LRS inhibitor, BC-LI-0186, could be developed as a cancer therapeutic in line with recent reports.³⁰ The classic mTOR inhibitors, rapalogs, are used in the coating of coronary stents, prevention of rejection after organ transplantation, treatment of tuberous sclerosis complex, and lymphangioleiomyomatosis.^31–34 Everolimus, a rapalog, has indications for the treatment of neuroendocrine tumors, advanced breast cancer in postmenopausal women who failed letrozole or anastrozole, and advanced renal cell carcinoma that failed sunitinib or sorafenib.^35–37 The main reason that rapalogs do not have wider indications in cancer is that their antitumor effect is modest whereas they have various adverse effects.

When comparing BC-LI-0186 with rapamycin in terms of cytotoxicity, there was no correlation between rapamycin and BC-LI-0186 (Supplemental Data 3). It also was encouraging that BC-LI-0186 showed a significant antitumor effect whereas the 2-week treatment of rapamycin did not show antitumor effect in the same experimental model used in this study (data not shown). This might be due to difference in the inhibitory mechanism: rapamycin inhibits mTORC1 by binding FKBP-12, whereas BC-LI-0186 inhibits mTORC1 by inhibiting binding of LRS to Rag GTPase. Moving the targeting site to the downstream of the signaling pathway could change the potency and efficacy of the drug.

However, a change in the targeting site of a drug may cause new problems. Long-term use of rapalogs has various side effects ranging from mild stomatitis, rash, increased susceptibility to infectious disease, diabetes, to interstitial pneumonitis leading drug discontinuation.³⁸ Because this study had a primary goal of confirming the efficacy of the drug, investigation on the adverse effects was partially done. There were no discernible changes in the appearance, behavior, or body weight in the experimental animals during the 2 weeks of treatment, but biochemical, hematologic, and other additional careful investigations are needed to clarify the short-term and long-term adverse effect of BC-LI-0186.

Along with the studies on the side effects, additional investigation need to be preceded for therapeutic application of this drug. This study confirmed efficacy by measuring changes in tumor size after 2 weeks of short-term treatment. For effective long-term cancer management, studies on the treatment cycle, frequency and duration of therapy are needed and once these are determined, the additional observation is needed to identify overall survival is significantly different to the control group.

The direct effect of LRS and its inhibitor, BC-LI-0186, on AKT signaling was not been predicted. However, some interesting findings between BC-LI-0186 and AKT have been observed in this study; among other things, the inverse correlation between p-AKT and LRS expression in unstimulated NSCLC. This finding suggested that LRS might be involved in negative feedback loop on the AKT signaling loop composed of mTORC1–pS6K–IRS. On the other hand, inhibition of p-AKT by increased concentration and exposure time to BC-LI-0186 in the cancer cells, and decreased expression of p-AKT in the tumor tissues after 2 weeks of BC-LI-0186 treatment, may be attributed to the cell death rather than its direct effect on AKT.

The TP53 mutation, one of the most frequently observed variations in various cancers, confers resistance to chemotherapeutic agents and reduces their therapeutic effects.³⁹ In a small pilot study using K-ras:p53^fl/fl mice, BC-LI-0186 did not show significant tumor reduction (Supplemental Data 4). This finding suggests that loss of TP53 function can affect the response of mice to BC-LI-0186. However, subsequent experiments using NSCLC cell lines, which lack functional TP53, did not support this finding, because several cell lines showed high or moderate sensitivity to BC-LI-0186 in terms of cytotoxicity, whereas the remaining cells were not sensitive. To clarify the antitumor effect of LRS inhibitor on the cancer with TP53 mutation, confirmation is required with various models.

In conclusion, LRS is frequently overexpressed in NSCLC tissues, and its expression correlates with that of pS6, a marker of mTORC1 activity. A novel LRS inhibitor, BC-LI-0186, inhibits mTORC1 signaling and has cytotoxic effects in NSCLC cells and antitumor effects in a K-ras mouse lung cancer model. This study suggests that BC-LI-0186 inhibits the noncanonical, mTORC1-activating function of LRS and provides a novel therapeutic strategy for NSCLC.

Supplemental Material

Supp_data_1 – Supplemental material for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Supplemental material, Supp_data_1 for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer by Eun Young Kim, Jin Gu Lee, Jung Mo Lee, Arum Kim, Hee Chan Yoo, Kibum Kim, Minji Lee, Chulho Lee, Gyoonhee Han, Jung Min Han and Yoon Soo Chang in Therapeutic Advances in Medical Oncology

Supplemental Material

Supp_data_2 – Supplemental material for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Supplemental material, Supp_data_2 for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer by Eun Young Kim, Jin Gu Lee, Jung Mo Lee, Arum Kim, Hee Chan Yoo, Kibum Kim, Minji Lee, Chulho Lee, Gyoonhee Han, Jung Min Han and Yoon Soo Chang in Therapeutic Advances in Medical Oncology

Supplemental Material

Supp_data_3 – Supplemental material for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Supplemental material, Supp_data_3 for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer by Eun Young Kim, Jin Gu Lee, Jung Mo Lee, Arum Kim, Hee Chan Yoo, Kibum Kim, Minji Lee, Chulho Lee, Gyoonhee Han, Jung Min Han and Yoon Soo Chang in Therapeutic Advances in Medical Oncology

Supplemental Material

Supp_data_4 – Supplemental material for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Supplemental material, Supp_data_4 for Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer by Eun Young Kim, Jin Gu Lee, Jung Mo Lee, Arum Kim, Hee Chan Yoo, Kibum Kim, Minji Lee, Chulho Lee, Gyoonhee Han, Jung Min Han and Yoon Soo Chang in Therapeutic Advances in Medical Oncology

Footnotes

Funding

This work was supported by the Global Frontier Project (grant numbers NRF-2013M3A6A4072536 and NRF-2014M3A6A4074817) and the Basic Science Research Program (grant number 2018R1A6A1A03023718) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Supplemental material

Supplemental material for this article is available online.

ORCID iD

Yoon Soo Chang

References

Siegel

Miller

Jemal

Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.

Chang

Choi

Lee

JC.

Mechanisms of epidermal growth factor receptor tyrosine kinase inhibitor resistance and strategies to overcome resistance in lung adenocarcinoma. Tuberc Respir Dis 2016; 79: 248–256.

Park

Choi

Kim

Aminoacyl-tRNA synthetase-interacting multifunctional proteins (AIMPs): a triad for cellular homeostasis. IUBMB Life. 2010; 62: 296–302.

Lee

Cho

Park

et al . Aminoacyl-tRNA synthetase complexes: beyond translation. J Cell Sci 2004; 117(Pt 17): 3725–3734.

Kim

You

Hwang

Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer 2011; 11: 708–718.

Arnez

Moras

Structural and functional considerations of the aminoacylation reaction. Trends Biochem Sci 1997; 22: 211–216.

Cusack

Hartlein

Leberman

Sequence, structural and evolutionary relationships between class 2 aminoacyl-tRNA synthetases. Nucleic Acids Res 1991; 19: 3489–3498.

Ghanipour

Jirstrom

Ponten

et al . The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2949–2956.

Wakasugi

Slike

Hood

et al . Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem 2002; 277: 20124–20126.

10.

Greenberg

King

Kiosses

et al . The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells. FASEB J 2008; 22: 1597–1605.

11.

Levy

Fisher

DE.

Dual roles of lineage restricted transcription factors: the case of MITF in melanocytes. Transcription 2011; 2: 19–22.

12.

Ray

Jia

Yao

et al . A stress-responsive RNA switch regulates VEGFA expression. Nature 2009; 457: 915–919.

13.

Cusack

Yaremchuk

Tukalo

The 2 A crystal structure of leucyl-tRNA synthetase and its complex with a leucyl-adenylate analogue. EMBO J 2000; 19: 2351–2361.

14.

Jewell

Russell

Guan

KL.

Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 2013; 14: 133–139.

15.

Bonfils

Jaquenoud

Bontron

et al . Leucyl-tRNA synthetase controls TORC1 via the EGO complex. Mol Cell 2012; 46: 105–110.

16.

Han

Jeong

Park

et al . Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 2012; 149: 410–424.

17.

Avruch

Long

Ortiz-Vega

et al . Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 2009; 296: E592–E602.

18.

Kim

Lee

et al . Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction. Nat Commun 2017; 8: 732.

19.

Kim

et al . KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPases expression. Lung Cancer (Amsterdam, Netherlands) 2014; 85: 299–305.

20.

Karachaliou

Mayo

Costa

et al . KRAS mutations in lung cancer. Clin Lung Cancer 2013; 14: 205–214.

21.

Janku

Yap

Meric-Bernstam

Targeting the PI3K pathway in cancer: are we making headway?

Nat Rev Clin Oncol 2018; 15: 273–291.

22.

Sancak

Peterson

Shaul

et al . The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (New York, NY) 2008; 320: 1496–1501.

23.

Shin

Choi

Kim

et al . Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma. Lung Cancer (Amsterdam, Netherlands) 2015; 89: 13–18.

24.

Jackson

Willis

Mercer

et al . Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243–3248.

25.

Kim

et al . AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. Cancer Lett 2015; 358: 85–91.

26.

Wang

Ducker

Barczak

et al . The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci USA 2011; 108: 15201–15206.

27.

Betz

Hall

MN.

Where is mTOR and what is it doing there?

J Cell Biol 2013; 203: 563–574.

28.

Blanco

Iwakawa

Tang

et al . A gene-alteration profile of human lung cancer cell lines. Hum Mutat 2009; 30: 1199–1206.

29.

Mahoney

Choudhury

Davies

et al . LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009; 100: 370–375.

30.

Gao

Yao

et al . A human leucyl-tRNA synthetase as an anticancer target. Onco Targets Ther 2015; 8: 2933–2942.

31.

Lozano

Serrador

Lopez-Palop

et al . Immediate and long-term results of drug-eluting stents in mammary artery grafts. Am J Cardiol 2015; 116: 1695–1699.

32.

Waldner

Fantus

Solari

et al . New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol 2016; 82: 1158–1170.

33.

Brakemeier

Bachmann

Budde

Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. Pediatr Nephrol (Berlin, Germany) 2017; 32: 1137–1144.

34.

McCormack

Inoue

Moss

et al . Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595–1606.

35.

Yao

Fazio

Singh

et al . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet (London, England) 2016; 387: 968–977.

36.

Baselga

Campone

Piccart

et al . Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520–529.

37.

Motzer

Escudier

Oudard

et al . Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (London, England) 2008; 372: 449–456.

38.

Kim

Blenis

Rapamycin: one drug, many effects. Cell Metab 2014; 19: 373–379.

39.

Aas

Børresen

A-L

Geisler

et al . Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.61 MB

0.84 MB

1.23 MB

5.37 MB